Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00306592 · ClinicalTrials.gov registry record · Phase 3
Natalizumab Re-Initiation of Dosing
A Phase 3 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 3
- Development phase
- 404
- Enrollment target
NCT00306592 is a Phase 3 study that has completed, run by Biogen. The registered enrollment target is 404 participants.
The verdict
NCT00306592, a Phase 3 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 404 participants
- Enrollment target
Study Summary
The primary objectives of this study are to further evaluate the safety of natalizumab (Tysabri®) monotherapy by evaluating the risk of hypersensitivity and immunogenicity following re-exposure to natalizumab, and to confirm the safety of switching to natalizumab from interferon beta (IFN-β), glatiramer acetate (GA), or other multiple sclerosis (MS) therapies.
Interventions
- BIOLOGICAL BG00002 (natalizumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 404 participants |
| Start Date | 2006-03 |
| Est. Completion | 2008-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00306592
The ClinicalTrials.gov registry entry for NCT00306592 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 404 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BG00002 (natalizumab) is the first listed.
NCT00306592 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00306592 about?
NCT00306592 is a clinical study titled "Natalizumab Re-Initiation of Dosing". The primary objectives of this study are to further evaluate the safety of natalizumab (Tysabri®) monotherapy by evaluating the risk of hypersensitivity and immunogenicity following re-exposure to natalizumab, and to confirm the safety of switching to natalizumab from interferon beta (IFN-β), glatir...
What is the current status of trial NCT00306592?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 404 participants. The study started on 2006-03. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00306592?
The interventions under investigation include: BG00002 (natalizumab) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00306592?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.